Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:DNLI NASDAQ:ETNB NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$8.26+3.3%$7.42$6.10▼$28.67$554.45M1.47307,365 shs588,833 shsDNLIDenali Therapeutics$15.65+5.0%$14.52$10.57▼$33.33$2.18B1.32.11 million shs1.84 million shsETNB89BIO$14.81-0.1%$10.73$4.16▼$15.06$2.20B1.279.48 million shs1.13 million shsSRPTSarepta Therapeutics$23.38+1.1%$18.85$10.41▼$138.81$2.26B0.516.35 million shs10.51 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+3.25%-0.84%+18.00%+2.10%-64.90%DNLIDenali Therapeutics+5.03%+4.96%+0.97%+1.95%-41.45%ETNB89BIO-0.13%+0.82%+72.81%+37.38%+99.87%SRPTSarepta Therapeutics+1.12%+21.01%+32.84%+22.60%-80.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$8.26+3.3%$7.42$6.10▼$28.67$554.45M1.47307,365 shs588,833 shsDNLIDenali Therapeutics$15.65+5.0%$14.52$10.57▼$33.33$2.18B1.32.11 million shs1.84 million shsETNB89BIO$14.81-0.1%$10.73$4.16▼$15.06$2.20B1.279.48 million shs1.13 million shsSRPTSarepta Therapeutics$23.38+1.1%$18.85$10.41▼$138.81$2.26B0.516.35 million shs10.51 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+3.25%-0.84%+18.00%+2.10%-64.90%DNLIDenali Therapeutics+5.03%+4.96%+0.97%+1.95%-41.45%ETNB89BIO-0.13%+0.82%+72.81%+37.38%+99.87%SRPTSarepta Therapeutics+1.12%+21.01%+32.84%+22.60%-80.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.50Moderate Buy$22.22169.03% UpsideDNLIDenali Therapeutics 3.00Buy$33.50114.06% UpsideETNB89BIO 2.40Hold$25.8174.29% UpsideSRPTSarepta Therapeutics 2.07Hold$39.0466.98% UpsideCurrent Analyst Ratings BreakdownLatest BCYC, DNLI, SRPT, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025DNLIDenali TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SRPTSarepta TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$14.00 ➝ $16.009/27/2025BCYCBicycle TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DNLIDenali TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SRPTSarepta TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/22/2025SRPTSarepta TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$50.009/19/2025ETNB89BIORaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform9/19/2025ETNB89BIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.509/19/2025ETNB89BIOWolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$35.28M16.23N/AN/A$11.48 per share0.72DNLIDenali Therapeutics$330.53M6.92N/AN/A$8.53 per share1.83ETNB89BION/AN/AN/AN/A$3.34 per shareN/ASRPTSarepta Therapeutics$2.48B0.92$2.46 per share9.49$15.99 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$169.03M-$3.51N/AN/AN/A-1,257.00%-32.43%-26.80%10/30/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A2.14N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest BCYC, DNLI, SRPT, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025DNLIDenali Therapeutics-$0.76N/AN/AN/A$1.00 millionN/A11/5/2025Q3 2025SRPTSarepta Therapeutics$0.02N/AN/AN/A$331.51 millionN/A10/30/2025Q3 2025BCYCBicycle Therapeutics-$1.05N/AN/AN/AN/AN/A8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/8/2025Q2 2025BCYCBicycle Therapeutics-$0.95-$1.14-$0.19-$1.14$9.43 million$2.90 million8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A10.3910.39DNLIDenali Therapeutics0.0110.2710.27ETNB89BIO0.0715.1915.19SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%DNLIDenali Therapeutics92.92%ETNB89BION/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics22.90%DNLIDenali Therapeutics12.50%ETNB89BIO2.60%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.31 million53.44 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableBCYC, DNLI, SRPT, and ETNB HeadlinesRecent News About These CompaniesWhat's Going On Sarepta Stock On Wednesday?October 8 at 11:19 AM | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst UpgradeOctober 8 at 10:38 AM | marketbeat.comRoyal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00October 8 at 9:39 AM | marketbeat.comA Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price GainsOctober 6 at 9:47 AM | finance.yahoo.com25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 CapitalOctober 6 at 4:19 AM | marketbeat.comSarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial ResultsOctober 3, 2025 | insidermonkey.comSarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian PlayOctober 3, 2025 | seekingalpha.comSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society CongressOctober 3, 2025 | businesswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 10.4% - What's Next?October 2, 2025 | marketbeat.comGenerali Investments CEE investicni spolecnost a.s. Grows Position in Sarepta Therapeutics, Inc. $SRPTOctober 1, 2025 | marketbeat.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30, 2025 | businesswire.comTempus Wealth Planning LLC Has $353,000 Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 29, 2025 | marketbeat.comCantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)September 25, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Hold from Evercore ISISeptember 25, 2025 | theglobeandmail.comKuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law FirmSeptember 24, 2025 | prnewswire.comAssenagon Asset Management S.A. Purchases 155,358 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 23, 2025 | marketbeat.comBMO upgrades Sarepta on Elevidys uptake, pipeline prospectsSeptember 22, 2025 | au.investing.comBMO Capital Upgrades Sarepta Therapeutics (SRPT)September 22, 2025 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Outperform at BMO Capital MarketsSeptember 22, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 5.2% - Still a Buy?September 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCYC, DNLI, SRPT, and ETNB Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$8.26 +0.26 (+3.25%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$8.38 +0.12 (+1.45%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Denali Therapeutics NASDAQ:DNLI$15.65 +0.75 (+5.03%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$15.57 -0.08 (-0.50%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.89BIO NASDAQ:ETNB$14.81 -0.02 (-0.13%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$14.82 +0.01 (+0.10%) As of 10/8/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Sarepta Therapeutics NASDAQ:SRPT$23.38 +0.26 (+1.12%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$23.26 -0.11 (-0.49%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
